Symbiotec Pharmalab
SYMBIOTEC NSE
Symbiotec Pharmalab
HealthcareNSE: SYMBIOTEC BSE: 544889 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapMarket Cap
₹7,117 Cr
P/E Ratio
66.6
EBITDA
₹241 Cr
Return on Equity
9.56%
Debt to Equity
0.34
Book Value
₹202.32
52W High
₹1,193.7
52W Low
₹934.2
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
3- Promoter holding is low: 33.3%
- Company has a low return on equity of 12.9% over last 3 years.
- Company might be capitalizing the interest cost
Growth Rate
Revenue Growth
15.38% higher than
3Y
Net Income Growth
13.42% lower than
3Y
Cash Flow Change
269% higher than
3Y
ROE
-19.66% lower than
3Y
ROCE
-3.26% higher than
3Y
EBITDA Margin (Avg.)
1.28% lower than
3Y
Quarterly Results
| Particulars | Jun 2025 |
|---|---|
| Sales | 203 |
| Expenses | 145 |
| Operating Profit | 58 |
| OPM % | 29% |
| Other Income | 3 |
| Interest | 5 |
| Depreciation | 11 |
| PBT | 45 |
| Tax % | 33% |
| Net Profit | 30 |
| EPS in Rs | 46.99 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 633 | 682 | 567 | 716 | 752 | 869 |
| Expenses | 438 | 550 | 497 | 544 | 549 | 630 |
| Operating Profit | 195 | 131 | 70 | 172 | 203 | 239 |
| OPM % | 31% | 19% | 12% | 24% | 27% | 27% |
| Other Income | 7 | 3 | 6 | 7 | 4 | -6 |
| Interest | 7 | 3 | 8 | 8 | 17 | 26 |
| Depreciation | 22 | 26 | 29 | 39 | 43 | 53 |
| PBT | 173 | 105 | 39 | 132 | 147 | 153 |
| Tax % | 28% | 27% | 38% | 23% | 34% | 28% |
| Net Profit | 123 | 78 | 23 | 100 | 97 | 110 |
| EPS in Rs | 113 | 70.89 | 21.48 | 91.49 | 152 | 17.51 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 13 |
| Reserves | 510 | 588 | 611 | 704 | 804 | 1,137 |
| Borrowings | 47 | 65 | 218 | 247 | 544 | 391 |
| Other Liabilities | 200 | 152 | 151 | 326 | 220 | 240 |
| Total Liabilities | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
| Fixed Assets | 261 | 280 | 299 | 448 | 438 | 1,120 |
| CWIP | 28 | 40 | 182 | 208 | 568 | 64 |
| Investments | 5 | 5 | 5 | 4 | 1 | 4 |
| Other Assets | 474 | 490 | 504 | 628 | 572 | 592 |
| Total Assets | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 174 | 18 | 69 | 188 | 47 | 175 |
| Investing | -96 | -32 | -220 | -206 | -307 | -227 |
| Financing | -79 | 15 | 146 | 22 | 278 | 36 |
| Net Cash Flow | -1 | 1 | -5 | 3 | 19 | -16 |
| Free Cash Flow | 87 | -55 | -155 | -22 | -261 | -50 |
| CFO/OP | 112 | 36 | 124 | 129 | 40 | 99 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 68 | 77 | 72 | 64 | 85 | 83 |
| Inventory Days | 308 | 252 | 305 | 382 | 321 | 274 |
| Days Payable | 155 | 91 | 110 | 259 | 109 | 160 |
| Cash Conversion Cycle | 221 | 238 | 267 | 187 | 298 | 197 |
| Working Capital Days | 86 | 121 | 107 | 76 | -3 | -22 |
| ROCE % | — | 18% | 6% | 16% | 14% | 13% |
Documents
2
Board Meeting Intimation for Prior Intimation Of The Meeting Of The Board Of Symbiotec Pharmalab Limited ('The Company') To Be Held On September 21, 2026
11 Sep - Board meets on 21 Sep 2026 to approve Q1 FY27 standalone and consolidated results. 11 Sep - Board meets on 21 Sep 2026 to approve Q1 FY27 standalone and consolidated results.
Frequently Asked Questions about Symbiotec Pharmalab
What does Symbiotec Pharmalab Ltd do?
Symbiotec is a research-driven, science-
based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal
Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale
Steroid manufacturer into a fully integrated global ...
Where is Symbiotec Pharmalab Ltd (SYMBIOTEC) listed?
Symbiotec Pharmalab Ltd trades as SYMBIOTEC on the NSE and under code 544889 on the BSE.
Which sector does Symbiotec Pharmalab Ltd belong to?
Symbiotec Pharmalab Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Symbiotec Pharmalab Ltd?
Symbiotec Pharmalab Ltd has a market capitalisation of ₹7,117 Cr, which places it in the Mid Cap band.
What is the PE ratio of Symbiotec Pharmalab Ltd?
Symbiotec Pharmalab Ltd trades at a PE ratio of 66.60, against a book value of ₹202.32 per share.
What is the 52-week high and low of Symbiotec Pharmalab Ltd?
Over the last 52 weeks Symbiotec Pharmalab Ltd has traded between ₹934.2 and ₹1,193.7.
What is the Return on Equity (ROE) of Symbiotec Pharmalab Ltd?
Symbiotec Pharmalab Ltd reported a return on equity of 9.56%. Its debt-to-equity ratio is 0.34.
Company Information
Symbiotec is a research-driven, science- based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale Steroid manufacturer into a fully integrated global platform.[1]
Listed 2026-09-01
Face Value ₹ 2
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SYMBIOTEC.md for Symbiotec Pharmalab Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.